Effectiveness of Low-Dose Sacubitril Valsartan versus Perindopril in the Treatment of Elderly Patients with HFrEF and Its Effect on Hemodynamics and Cardiac Remodeling
ZHANG Lijuan, LIU Hui, ZHANG Lina, et al
Characteristic Medical Center of Chinese PLA Rocket Force, Beijing 100088, China
Abstract：Objective: To explore the effect of low-dose sacubitril/valsartan and perindopril in the treatment of elderly patients with heart failure with reduced ejection fraction (HFrEF) and the influence on hemodynamics and cardiac remodeling. Methods: The clinical data of 133 elderly patients with HFrEF admitted to the hospital from January 2020 to October 2022 were retrospectively analyzed, and the patients were divided into observation group (conventional treatment+low-dose sacubitril/valsartan, n=69) and control group (conventional treatment+perindopril, n=64) according to the treatment methods. Cardiac function grading, cardiac remodeling indicators, hemodynamic indicators and serum cardiac function indicators were compared between the two groups before treatment and at 3 months of treatment. Adverse drug reactions were recorded in the two groups. Results: The NYHA cardiac function grading in observation group was significantly better than that in control group at 3 months of treatment (Z=2.112, P=0.035). At 3 months of treatment, the LVEF in the two groups was higher than that before treatment (P<0.05) while the LVEDd and LVESD were lower than those before treatment (P<0.05), and the differences before and after treatment in the two groups showed statistical significance (P<0.05). The HR in observation group at 3 months of treatment was lower than that before treatment (P<0.05) while the CO and CI were higher than those before treatment (P<0.05), and the differences before and after treatment revealed statistical significance in the two groups (P<0.05). The levels of serum NT-proBNP, hs-CRP and cTnT in observation group at 3 months of treatment were lower than those before treatment (P<0.05), and the differences before and after treatment in the two groups revealed statistical significance (P<0.05). There were no statistically significant differences in the incidence rates of adverse reactions such as hypotension, dry cough and dizziness between the two groups (P>0.05). Conclusion: Low-dose sacubitril/valsartan and perindopril are safe and effective in the treatment of HFrEF. The former one is more effective in improving the cardiac function and cardiac remodeling and stabilizing the hemodynamics.
张丽娟, 刘辉, 张丽娜, 辛超, 廖翔, 郑程荣, 郑新民. 小剂量沙库巴曲缬沙坦与培哚普利治疗老年HFrEF患者的效果及对血流动力学心脏重构的影响[J]. 河北医学, 2023, 29(8): 1388-1392.
ZHANG Lijuan, LIU Hui, ZHANG Lina, et al. Effectiveness of Low-Dose Sacubitril Valsartan versus Perindopril in the Treatment of Elderly Patients with HFrEF and Its Effect on Hemodynamics and Cardiac Remodeling. HeBei Med, 2023, 29(8): 1388-1392.
[1] Heidenreich PA,Bozkurt B,Aguilar D,et al.2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J].Circulation,2022,145(18):895-1032. [2] Murphy SP,Ibrahim NE,Januzzi JL Jr.Heart failure with reduced ejection fraction:a review[J].JAMA,2020,324(5):488-504. [3] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):30. [4] Pieske B,Tschope C,de Boer RA,et al.How to diagnose heart failure with preserved ejection fraction:the HFA-PEFF diagnostic algorithm:a consensus recommendation from the heart failure association (HFA) of the european society of cardiology (ESC)[J].Eur Heart,2019,40(40):3297-3317. [5] Bredy C,Ministeri M,Kempny A,et al.New York Heart Association (NYHA) classification in adults with congenital heart disease:relation to objective measures of exercise and outcome[J].Eur Heart Qual Care Clin Outcomes,2018,4(1):51-58. [6] Borlaug BA.Evaluation and management of heart failure with preserved ejection fraction[J].Nat Rev Cardiol,2020,17(9):559-573. [7] 李蕾,杨红,王韶屏,等.沙库巴曲缬沙坦钠与培哚普利吲达帕胺在高龄老年高血压合并射血分数保留心力衰竭的短期治疗比较[J].心肺血管病杂志,2021,40(11):1117-1121. [8] 刘海燕,宋毓青,陈永福,等.沙库巴曲缬沙坦对射血分数降低型慢性心力衰竭患者的临床疗效及对B型脑钠肽和C反应蛋白水平的影响[J].中国医药,2022,17(1):15-18. [9] Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America[J].Card Fail,2017,23(8):628-651. [10] 卢运专,封远锋,赵会必,等.伊伐布雷定治疗HFrEF患者的疗效及其对心脏结构功能的影响[J].心血管康复医学杂志,2021,30(3):287-291. [11] Mann DL,Givertz MM,Vader JM,et al.Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction:a randomized clinical trial[J].JAMA Cardiol,2022,7(1):17-25. [12] Mohebi R,Liu Y,Pina IL,et al.Dose-response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction[J].Am Coll Cardiol,2022,80(16):1529-1541. [13] 本木措,王峰,倪黎,等.小剂量沙库巴曲缬沙坦与培哚普利治疗射血分数降低慢性心力衰竭的疗效与安全性对比研究[J].中国实用内科杂志,2021,41(6):526-530. [14] 赵东坡,冯倩,师淼,等.不同剂量沙库巴曲缬沙坦联合他汀类药物治疗心房颤动合并射血分数保留心力衰竭的效果[J].解放军医药杂志,2022,34(6):100-103. [15] 黄芃菲,卢成志.小剂量沙库巴曲缬沙坦用于治疗心力衰竭合并慢性肾脏病1~3期患者的研究[J].天津医药,2022,50(9):993-997.
2023, Vol. 29 
冀公网安备13080202000677号